Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to ...

Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma “took to heart” data ...

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire ...

After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for ...

A patient has died after receiving the high dose of Neurogene’s Rett syndro | A patient has died after receiving the high ...

AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a ...

Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...

Enveda, a company using artificial intelligence to boost nature-based drug discovery, is envisioning clinical success with a ...

After collecting an FDA greenlight earlier this year, BD is launching a real-world study to see if its self-collection kits ...

Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...

They need to find a bigger venue,” an attendee mutters as they pull their coat tight and brave the British rain to find one ...

Genmab's Anthony Pagano sat down with Fierce Biotech at the Jefferies conference in London to talk M&A, asset ownership and ...